The relative abundance of OLCFA in body lipids of patients with defective propionate metabolism (PA, MMA) can be used for monitoring these patients, inasmuch as it is influenced by the clinical management (I). Increased.accumulation of OLCFA has already been found in newborns who had died with one of these disorders shortly after birth (2) (3) (4) (5) . Here we show that in affected fetuses increased OLCFA production from the precursor amino acids of propionyl-CoA is a process that starts early in fetal life. It appears that excess accumulation of OLCFA in a fetus with vitamin B12-responsive MMA could be reduced by prenatal therapy.
PATIENTS AND METHODS both fetuses, PA was diagnosed prenatally by means of the determination of methylcitrate in amniotic fluids and by enzymatic studies in cultured amniocytes. Activity of propionyl-CoA carboxylase measured as enzyme-dependent incorporation of I4C-bicarbonate into acid-nonvolatile products (6) in cultured amniocytes was 14 and 5.3 pmol/mg protein x min, respectively (controls: mean + SD, 1297 * 668; range, 472-2629; n = 14).
In each fetus, abortion was induced at wk 21 of gestation. After abortion, erythrocytes, plasma, and whole blood, as well as liver, brain, and S.C. tissue, were obtained and immediately frozen at -20°C.
M.B., the second child of a healthy and unrelated couple, was born at term. The first child had suffered from ventricular septa1 defect and had died at 3 wk of age of unknown cause. M.B. presented with vomiting, hypotonia, respiratory insufficiency, and coma at 5 d of age. He was severely hyperammonemic (1.8 mmol/L). The gas chromatography-mass spectrometry of urine suggested a diagnosis of PA, which was confirmed later by enzymatic analysis in cultured fibroblasts. Activity of propionylCoA carboxylase in fibroblasts was 7.0 pmol/mL protein x min (controls: mean + SD, 1087 f 356; range, 564-2005; n = 21).
At d 9, continous arteriovenous hemofiltration and dietary management was begun in the University Children's Hospital, Innsbruck. At d 1 I, 13, 23, and 44, the fatty acid composition in lipids of red cell membranes and plasma was studied. Despite a successful treatment of initial coma, the patient died at the age of 3 mo during a metabolic crisis.
M.Y., a boy, is the second child of healthy consanguineous Turkish parents. Pregnancy and delivery were normal. A 3-y-old daughter is healthy; two children had died of unknown causes in Turkey at 2 wk of age. The patient presented at 9 d of age with hyperammonemia (650 pmol/L) and a slight metabolic acidosis and was treated with peritoneal dialysis. Gas chromatography of the urine showed a high excretion of methylmalonic acid (7.2 mol/mol creatinine). After peritoneal dialysis lasting for 3 d, he was started on a low-protein regimen supplemented with nontoxic amino acids, L-carnitine, and vitamin B12. It appeared that he suffered from vitamin B12-responsive MMA. Later, the diagnosis was confirmed in the patient's fibroblasts. Incorporation of I4C-propionate without hydroxycobalamin added was about 10% that of controls and showed a 3.5-fold increase with supplemented hydroxycobalamin (100 pg/L of culture medium). At the age of 20 mo, the boy was doing well. At d 9 and 24, the fattv acid comvosition in red cell and ~l a s m a livids was studied. Patients. Fetuses Ho 1 and Ho 2 were at risk for PA and
"
pregnancy at risk for vitamin ~,~-r e ;~o n s i v e MMA, amniocenteses were performed in the 16th gestational wk. In prenatal diagnosis performed gas chromatogra~hy-mass spectrometry analysis of amniotic fluid obtained at 16 gestational wk 404 WENDEL ET AL the mother was given high oral doses of vitamin BI2 (22.5 mg/d in three doses) starting in the 27th wk of gestation. On this treatment, the maternal urinary methylmalonate excretion was around 10.3 mmol/mol creatinine, which leveled off during the last 5 wk of gestation (7) . A clinically healthy female infant was born by spontaneous delivery at 4 1 wk of gestation. After birth, an increase in methylmalonate excretion was observed, reaching 2.1 mol/mol creatinine on the 3rd d of life. Administration of hydroxycobalamin by intramuscular injection (1 mg/2 d) was started on d 4. By this measure, methylmalonate excretion was successfully reduced. The OLCFA content was measured in the plasma lipids of cord blood. The diagnosis of vitamin BI2-responsive MMA was confirmed in the patient's fibroblasts by Dr. B. Fowler, Manchester, UK. Incorporation of '4C-propionate without hydroxycobalamin added was about 15% that of controls and reached the control range with supplemented hydroxycobalamin (1000 pg/L of culture medium).
Methods. Red blood cells were isolated from EDTA-blood and washed as described (8) . Plasma and erythrocytes were stored at -20°C until analysis. The cord blood of controls was collected into EDTA-tubes, and erythrocytes and plasma were separated within 24 h. Fetal tissues and tissues from deceased prematures were stored at -20°C until analysis.
The work-up of the red cell lipids was exactly as described previously (8) .
Lipids were extracted from 1.0 mL plasma with chloroform/ methanol (9) . The different lipid classes were separated on silica gel plates (Merck, Darmstadt, Germany) with a run of petroleum/ether/acetic acid (7512511, vol/vol/vol) and a run of chloroform/methanol/water (6512514, vol/vol/vol). The bands containing sterol esters, triglycerides, and phospholipids were identified by comparison with appropriate standards and removed by scraping. The fatty acids were transesterified with methanol and hydrochloric acid (10) .
The tissues (1-20 mg wet wt) were homogenized by use of a microdismembrator (Braun Melsungen, Germany) under liquid nitrogen (maximal power, 0.5 min). The tissue homogenates were extracted with 7.5 mL methanol/chloroform (211, vol/vol). After standing overnight in the dark at room temperature, 2.5 mL chloroform and 2.5 mL water were added. After shaking, the mixture was allowed to stand for 15 min on ice. Then it was centrifuged at 1500 x g (20 min, room temperature) and the supernatant was discarded. The lipid extracts (lower layers) were evaporated to dryness at 35°C. The residue was transesterified by base catalysis with sodium methoxide as described previously (8) . Analysis of the fatty acid methyl esters by capillary column gas liquid chromatography was exactly as we have described (8) . Fatty acids of 14-22 carbon length were identified by comparison with authentic standards.
In each sample, the proportions of the individual OLCFA-15-and 17-carbon saturated and 17-carbon monounsaturated fatty acids (C 15:0, C 17:0, C 17: 1)-as well as their sums were calculated and expressed as a percentage of the total C14-C22 fatty acids in the sample.
RESULTS
Different tissues of two fetuses of 2 1 wk gestation affected with PA contained much more OLCFA than tissues from premature or full-term controls (Table 1) . Among the specimens, the OLCFA content was highest in plasma sterol esters, liver, and S.C. tissue and lowest in brain.
The OLCFA levels in red cell and plasma lipids of two newborns with PA and MMA are shown in Table 2 . Plasma lipids in the PA patient contained higher amounts of OLCFA than those in the MMA patient. Both patients experienced a severe metabolic episode before they were diagnosed. In each lipid fraction studied, the high OLCFA level present shortly after birth t Cord blood at term, n = 2.
$ Deceased prematures, 26 gestational wk, n = 2. declined substantially during the first 4-6 wk of life while patients were on treatment.
We found normal OLCFA contents in cord blood lipids of a child with vitamin BIZ-responsive MMA who was treated prenatally with large doses of vitamin B12 given to the mother ( Table  3) . By extrapolation from our data in fetuses with PA and newborns with PA and MMA, as well as from the increased urinary methylmalonate excretion of the mother before institution of B12-therapy, this might indicate that at least during the last weeks of fetal life the production of excess OLCFA was reduced.
DISCUSSION
We showed that fetuses affected with a disorder of propionate degradation incorporate great amounts of OLCFA into body lipids. At approximately 20 wk of gestation, the OLCFA content in various lipids of fetuses with PA was very high and was similar to that found shortly after birth. Due to a transplacental gradient of free amino acids in favor of the fetus providing the fetus with optimal amino acid nutrition (for ref. see I I), relatively high concentrations of the free precursor amino acids-valine, isoleucine, methionine, and threonine-exist in fetal blood. This results in the formation of large amounts of propionyl-CoA in the tissues, which under the highly anabolic conditions of fetal life augments OLCFA production and incorporation into newly synthesized lipids. The fact that part of propionyl-CoA is eliminated from the fetus as propionate derivatives offers the possibility of prenatal diagnosis of PA and MMA by means of the determination of methylcitric acid in amniotic fluid (12) . Another class of propionyl-CoA-derived compounds found in amniotic fluids of fetuses with PA and MMA are methyl-branched dicarboxylic acids (I 3).
Elevated OLCFA were also found in erythrocyte and plasma lipids of newborns with PA and MMA. By extrapolation from our data, a higher accumulation of OLCFA could be expected for fetuses with PA than MMA. This is in line with the finding that the concentration of methylcitric acid in amniotic fluids of fetuses with PA is somewhat higher than in those with MMA (14) suggesting that the former have higher elevations of propionyl-CoA.
After birth, two facts may account for the observed decline of OLCFA in plasma and red cell lipids: I ) the physiologic shift in the fatty acid pattern of plasma lipids during the first 4 wk of age (1 5), which results in a reduction of the percentage of monounsaturated fatty acids-here heptadecenoic (C 17: 1) acid and 2) the lower provision of precursor amino acids during dietary treatment compared with fetal life leading to a decline in propionyl-CoA production. However, in the present cases the decrease could at least partly reflect recovery from the acute ketoacidotic episodes (see Fig. 2 of ref. 1) that both neonates experienced before first blood samples were taken.
It is likely that substantial amounts of propionyl-CoA and methylmalonyl-CoA during prenatal life cause injury to the fetus. In that respect, the highly active flux of propionyl-CoA into the OLCFA synthesis might have a beneficial and detoxicating effect by reducing the fetal propionyl-CoA pool. However, it cannot be answered whether great amounts of OLCFA in brain lipids, per se, are responsible for impaired neurologic development in those patients, as has been proposed (5).
The OLCFA might be regarded as a storage form of propionylCoA accumulating already in fetal life. During periods of strong tissue catabolism, such as in early days of life, the stimulated breakdown of adipose tissue might importantly contribute to the accumulation of extensive amounts of toxic propionyl-CoA in the mitochondria, and thus contribute to the severe illness of these patients.
Prenatal treatment of a fetus affected with vitamin BIZ-responsive MMA during the last 13 wk of gestation with large doses of vitamin BIZ given to the mother reduced the increased maternal excretion of methylmalonic acid and led to a normal OLCFA content in plasma lipids at birth. The pharmacologic vitamin dose was given to diminish the accumulation of various metabolites including propionyl-CoA by an increased flux through the defective methylmalonyl-CoA mutase step. Until now, the success of prenatal treatment could be followed only indirectly by monitoring methylmalonic acid in maternal urine (1 6). Although it was suggested that the more important effect of vitamin BIZtreatment was on fetal metabolism, it could not satisfactorily be clarified whether the decrease in maternal methylmalonic acid excretion could have resulted from an effect on fetal metabolism alone or on fetal and maternal metabolism combined (16) . The normal OLCFA content of cord plasma lipids in our patient appears to demonstrate more directly that in fact the metabolic block in the fetus was improved by vitamin BI2-treatment. Thus, OLCFA in cord blood lipids after birth might be an additional parameter for the evaluation of effectiveness of prenatal treatment of fetuses with vitamin B12-responsive MMA and perhaps also with holocarboxylase synthetase deficiency ( 1 7).
